Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05979064 · ClinicalTrials.gov registry record · NA
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
A NA study of Glioblastoma and Glioblastoma Multiforme, sponsored by Northwell Health.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05979064: Recruiting NA study of Glioblastoma and Glioblastoma Multiforme, sponsored by Northwell Health.
NCT05979064 is a NA study of Glioblastoma and Glioblastoma Multiforme that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 10 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05979064, a NA study of Glioblastoma and Glioblastoma Multiforme, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
Primary Outcome
Increase in tumor size relative to baseline will be measured using RANO and assessed by MRI throughout study at within 72 hours, 7 days, 30 days, 60 days, 120 days and 180 days. Rapidly progressive disease is defined as 25% growth relative to baseline.
Conditions Studied
Interventions
- PROCEDURE Laparoscopically harvested omental tissue autograft
Study Locations (1)
New York
- Lenox Hill Brain Tumor Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2027-04 |
| Phase | NA |
What NCT05979064 shows while recruiting
NCT05979064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (91% lower).
The record links to 8 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Laparoscopically harvested omental tissue autograft is the first listed.
NCT05979064 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05979064 about?
NCT05979064 is a clinical study titled "Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)". This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
What is the current status of trial NCT05979064?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2023-04-04. Estimated completion is 2027-04.
What conditions does trial NCT05979064 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, Glioma, Brain Cancer, High Grade Glioma.
What interventions are being tested in trial NCT05979064?
The interventions under investigation include: Laparoscopically harvested omental tissue autograft (PROCEDURE).
Who is sponsoring clinical trial NCT05979064?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05979064 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05979064's enrollment target sits among peer trials
10 189th of 199 higher than 6 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
RECRUITING · NA
-
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI